UK Parliament watchdog wants sluggish value-based pricing discussion for drugs clarified by March
This article was originally published in SRA
Executive Summary
The UK Parliament’s Health Select Committee which monitors England's Department of Health is calling for the department to work out plans for value-based pricing by the end of March1. The lack of progress and clarity on the new arrangements so far, it said, is “unacceptable”.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.